Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received the Drug Registration Certificate for Baclofen Tablets. The drug is indicated for severe but reversible muscle spasms caused by multiple sclerosis, and may have some efficacy for spasms caused by other spinal cord diseases. In 2025, the total sales of Baclofen Tablets in China's medical and retail markets reached 247 million yuan. As of the announcement date, Qianjin Xiangjiang Pharmaceutical's cumulative R&D investment in this drug was 5.88 million yuan. Qianjin Pharmaceutical achieved revenue of 970 million yuan in the first quarter of 2026, with a net profit attributable to the parent company of 75 million yuan.
ZhuZhou QianJin Pharmaceutical Co LtdSubsidiary received drug registration certificate for Baclofen Tablets, a new product approval.